Cat. No.: DIA-0243191
Product Information | |
---|---|
Synonyms | GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA |
Formula | C148H224N40O45.xC2HF3O2 |
Target | GLP Receptor |
Product Description | Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies. |
Format & Storage | |
---|---|
Format | Solid |
Color | White to light yellow |
Purity | 99.12% |
Shipping | Room temperature in the continental U.S. Other areas may vary. |
Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.